Feldene Flash

Quick links to important sections

Feldene Flash

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Feldene Flash

Property Description
Active ingredient Piroxicam
Form Oral Lyophilisate (Rapid-dissolving tablet)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain and inflammation
Origin Synthetic (Oxicam derivative)

Core Identity and Classification of Feldene Flash

Feldene Flash is a prescription-only medicinal product, distinguishing it from over-the-counter NSAIDs. Its active pharmaceutical ingredient is Piroxicam, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is chemically categorized as a synthetic oxicam derivative. This placement within the NSAID class confirms its intended systemic use to modulate the body's response to pain and inflammation. This specific classification is clinically recognized for its extended half-life compared to several other NSAID classes, establishing its role as an essential analgesic and anti-inflammatory agent.

The Rapid-Acting Lyophilisate Formulation

The medicine is supplied as an oral lyophilisate, a highly specialized and rapidly-dissolving tablet formulation intended solely for oral administration. This formulation is a key differentiating factor for Feldene Flash. It is engineered to disintegrate almost instantaneously upon contact with saliva in the mouth, promoting quick consumption without the need for water, which provides convenience. This technological design facilitates a rapid absorption of the active substance through the digestive tract when compared to traditional solid oral forms.

General Purpose: Managing Pain and Inflammation

The general therapeutic purpose of this product is to provide symptomatic relief by modulating the body's inflammatory response. The active substance achieves a general anti-inflammatory effect and a corresponding analgesic effect (pain relief) by inhibiting the formation of specific chemical messengers responsible for mediating pain signals and swelling. For example, it provides relief in situations where swelling and pain coexist. The use of the lyophilisate form is conceptually linked to achieving a necessary rapid onset of action for immediate pain and inflammation management.

What side effects are possible with Feldene Flash?

Possible Side Effects and Safety Information

The official safety information for this medicine, as documented by government regulatory agencies, focuses on serious potential risks and classified adverse reactions.

Serious Safety Warnings

Regulatory agencies emphasize two major, potentially fatal risks. These include:

  • Serious Cardiovascular (CV) Thrombotic Events: An increased risk of heart attack and stroke, which can be fatal. This risk may increase with the duration of use and in people with pre-existing heart disease. The medicine is contraindicated for treating pain right before or after coronary artery bypass graft (CABG) surgery.
  • Serious Gastrointestinal (GI) Adverse Events: An elevated risk of stomach or intestinal bleeding, ulceration, and perforation, which can occur without warning symptoms and may be fatal. This risk is greater in older adults and with longer use.

Frequency-Classified Adverse Reactions

Adverse reactions are formally documented and categorized based on the body system affected (System-Organ Class) and how often they occur. Common reactions (occurring in more than 2% of patients) include nausea, abdominal pain, constipation, flatulence, headache, dizziness, and swelling (edema).

Other serious, but rare, reactions documented in official labeling include severe skin conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as liver failure (fatal hepatitis).

Population-Specific Restrictions

Specific restrictions for use are documented for certain populations:

  • Pregnancy: Use is restricted during the later stages of pregnancy (starting at 30 weeks gestation) due to the risk of premature closure of the fetal ductus arteriosus, which can cause fetal heart harm.
  • Hypersensitivity: The medicine is contraindicated in patients who have experienced allergic reactions such as asthma, hives, or other allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).

To minimize potential risks, official documents specify that the lowest effective dosage should be used for the shortest duration necessary.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Piroxicam overdose documents a range of potential clinical manifestations that may occur following exposure exceeding recommended therapeutic levels. Documented presentations include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and stomach pain, alongside systemic effects such as headache, drowsiness, dizziness, tinnitus, and blurred vision.

Urgent Action Required

Overdose may escalate to severe or life-threatening outcomes affecting the central nervous system, renal function, or the cardiovascular system. Serious manifestations include convulsions (seizures), decreased consciousness leading to coma, low blood pressure (hypotension), and signs of severe gastrointestinal bleeding, which may present as bloody stools or vomiting material resembling coffee grounds. A decrease in urine production is also documented, indicative of potential acute renal compromise.

When any of these severe manifestations occur, regulatory authorities mandate that immediate medical attention must be sought. Official documentation specifies that management involves symptomatic and supportive treatment, including the potential use of activated charcoal and intensive monitoring of vital signs. Patients with pre-existing kidney or liver disease are noted to be at an increased risk for serious complications in an overdose situation. There is no specific antidote listed in the official prescribing information.

Therapeutic Uses of Feldene Flash

What Feldene Flash Treats: Main Uses and Benefits

The primary therapeutic role of Feldene Flash (Piroxicam) is to provide symptomatic relief by addressing symptoms related to inflammatory or irritative states in the body, which are generally disruptive. The medication is commonly used to help with conditions where functional stability becomes affected, such as chronic joint diseases. Feldene Flash is considered relevant for easing symptoms associated with conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.


Symptom Focus and Patient Benefit

This medication is utilized to provide supportive relief in established, long-term conditions and during phases when symptoms of a chronic condition suddenly escalate, known as acute flares. It assists patients by targeting a critical cluster of symptoms that interfere with daily functioning: joint pain, associated swelling, and stiffness. By mitigating these distressing manifestations, the medication helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

Quick Fact: Support for Inflammatory Joint Pain and Stiffness

Therapeutic Indications (Summary)

Feldene Flash is applied across domains where additional symptomatic support is needed, primarily for conditions involving persistent inflammation. This generally contributes to easing the overall symptom load associated with chronic inflammatory diseases and acute exacerbations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Feldene Flash (piroxicam) is generally prescribed for the symptomatic relief of certain inflammatory and degenerative rheumatic diseases like osteoarthritis and rheumatoid arthritis. It's a non-steroidal anti-inflammatory drug (NSAID) and is typically not a first-line treatment due to its risk profile.


Contraindications

Feldene Flash should not be used by individuals with:

  • A known allergy to piroxicam, aspirin, or other NSAIDs (which may trigger asthma, hives, or a severe allergic reaction).
  • An active or history of gastrointestinal ulceration, bleeding, or perforation.
  • Severe heart failure or kidney disease.
  • Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
  • Pregnancy, especially during the third trimester, as well as breastfeeding.
  • A bleeding disorder.

Precautions and High-Risk Groups

Patients must use this medication with caution, and may require closer monitoring or dose adjustment, if they have a history of high blood pressure, heart disease, fluid retention, liver impairment, or asthma not related to aspirin sensitivity. The risk of serious gastrointestinal and cardiovascular side effects is generally higher for elderly patients (over 70 years old) and those using certain other medications, such as anticoagulants or oral corticosteroids.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Piroxicam, the active substance in Feldene Flash, has documented interaction patterns primarily categorized by its metabolic pathway and its pharmacodynamic effects on clotting and blood pressure regulation, as defined by government regulatory documents.

Prohibited and Avoided Combinations

Due to a significantly heightened risk of bleeding and serious gastrointestinal events, the co-administration of Feldene Flash with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 Inhibitors, and analgesic doses of Aspirin is not generally recommended. Co-administration with Oral Anticoagulants, including Warfarin and newer agents like apixaban and rivaroxaban, is also officially advised against because it severely increases the risk of both gastrointestinal and non-gastrointestinal bleeding.

Metabolic and Exposure Effects

The medicine is primarily cleared from the body via the Cytochrome P450 2C9 (CYP2C9) enzyme. This metabolic pathway is linked to the potential for altered exposure of co-administered drugs. Regulatory information indicates that Feldene Flash may increase the plasma concentration and reduce the clearance of certain medicines, including Lithium, Digoxin, and Methotrexate. Individuals identified as CYP2C9 poor metabolizers demonstrate a reduced metabolic clearance, leading to high systemic plasma levels of piroxicam.

Pharmacodynamic Effects

Co-administration with blood pressure medicines, specifically ACE Inhibitors and Angiotensin Receptor Blockers (ARBs), may diminish their intended antihypertensive effect. This combination also carries a documented caution regarding the potential for renal function deterioration in high-risk patients, such as the elderly. The consumption of alcohol is explicitly associated with an increased risk of serious gastrointestinal complications.

Mechanism of Action

Non-selective Inhibition of Cyclooxygenase Enzymes

The drug initiates its mechanism by acting as a non-selective, reversible inhibitor of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This molecular action directly and substantially limits the conversion of arachidonic acid into prostaglandins (PGs), which are crucial lipid mediators that govern inflammatory and nociceptive signaling in biological systems. This mechanistic domain initiates the molecule's modulation of systemic physiological responses.


Suppression of Peripheral Mediators and Nociceptor Sensitization

The resulting reduction in prostaglandin synthesis chemically suppresses local inflammatory mediators and modulates the body's response to tissue injury. By limiting PGE2 availability, the mechanism reduces the chemical sensitization of peripheral nociceptors (pain receptors) and decreases local vascular permeability. This action results in the reduction of nociceptor sensitization and attenuates vascular permeability changes in the tissue.


Mechanistic Role of the Lyophilisate Formulation

The specialized, rapidly dissolving lyophilisate formulation is designed to accelerate the delivery of Piroxicam for systemic absorption. This rapid delivery leads to the accelerated presentation of Piroxicam for systemic absorption, which influences the kinetics of COX enzyme inhibition.

Dosage and Administration Information

How to Use Feldene Flash

Feldene Flash (Piroxicam) is administered according to specific principles to ensure standardized usage.

Administration and Frequency

The primary route of administration for Feldene Flash is oral. The oral lyophilisate, or rapid-dissolving tablet, is designed to be placed on the tongue where it disperses rapidly in saliva, allowing it to be swallowed with or without water, or it may be swallowed whole. Administration is generally instructed to occur with or immediately after food to align with conventional NSAID usage protocols. Due to the active substance's long half-life, the standard maintenance regimen involves dosing the medicine once daily.

Official Dosing Regimens

Dosing is founded on the principle of using the lowest effective dosage for the shortest duration necessary to achieve symptomatic control. The maximum daily dose for all indications in adults must not exceed 20 mg.

Indication Context Official Dosing Principle Clinical Parameter
Chronic Conditions (Maintenance) 20 mg once daily, or 10 mg once daily for some patients. Maximum 20 mg daily
Acute Exacerbations (Short-Term) 40 mg daily for the first two days, followed by 20 mg daily thereafter. Use for the shortest necessary duration

Procedural Constraints

The benefit of continued treatment for chronic conditions must be formally re-evaluated by the prescriber, with initial reassessment recommended within the first 14 days of initiating therapy. Dosage adjustments are necessary for specific populations, particularly for older adults and patients with known renal impairment, where the minimum effective dose and close monitoring are required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Feldene Flash

The Research Foundation for Chronic Inflammatory Conditions

The research base for Piroxicam, the active ingredient in Feldene Flash, established the evidence base for Piroxicam, exploring its use in conditions characterized by fluctuating or episodic manifestations of pain and inflammation. This evidence foundation relies on studies where responses were observed over defined time intervals in the studied populations.

Evidence in Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

Research examining Piroxicam was evaluated in the context of conditions marked by functional limitations and systemic or functional imbalance and consists largely of Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that consolidate findings from many individual studies. These trials were primarily conducted with adults diagnosed with classical forms of Osteoarthritis and Rheumatoid Arthritis.

Studies monitored various outcomes related to physical discomfort and daily functioning. Findings describe patterns observed in the studies; research highlighted measurements of symptom variability in both patient-reported pain levels and objective joint metrics during the study periods. However, the evidence quality varies across studies, and long-term effects are not fully established. Research contributes to understanding short-term changes, but there is limited information for long-term outcomes, such as sustained response over many years.

Research into the Rapid-Acting (Flash) Formulation

The Feldene Flash product uses an oral lyophilisate formulation, and dedicated research examined the specific performance characteristics of this design. These research settings involved controlled trials where the fast-dissolving tablet was compared against the conventional solid tablet of the same medicine. The primary outcomes studied were those describing episodic or acute changes, specifically the time taken to report initial pain relief—the onset of symptom change. Studies reported that the fast-dissolving formulation was observed to have a shorter time to the onset of symptom change compared to the conventional tablet in the observed populations.

Long-Term Follow-up and Durability of Response

Studies monitoring the use of Piroxicam over defined time intervals have revealed that while substantial short-term data exists, evidence related to long-term outcomes and the durability of response is limited. Findings describe group patterns related to changes measured during the study period, but research highlights that follow-up durations were limited in a high number of the trials reviewed. Therefore, long-term effects are not fully established, and this constitutes a key evidence limitation across the chronic inflammatory indications.

Areas of Research Uncertainty and Evidence Gaps

The evidence landscape, while extensive, contains several areas where certainty remains low or data are still emerging. A major limitation is that evidence quality varies across studies, often due to sample sizes that were modest or follow-up durations that were limited. Long-term effects are not fully established, and there is limited information for outcomes related to systemic or functional imbalance over periods exceeding several months.

Key Studies & References

  1. Rheumatoid arthritis in adults: management (NICE Clinical Guideline NG100)

Frequently Asked Questions (FAQ)

Common questions about Feldene Flash (FAQ)

Q: Is Feldene Flash the same as regular Feldene (Piroxicam)?

A: Feldene Flash contains the same active medicinal ingredient, Piroxicam. The key difference, according to official product information, is the formulation. Feldene Flash is an oral lyophilisate, which is a rapid-dissolving tablet designed to dissolve quickly compared to a standard Piroxicam capsule or tablet.

Q: What is the difference between Feldene Flash and ibuprofen?

A: Both are classified as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). However, official pharmacokinetics data indicates that Piroxicam, the active ingredient in Feldene Flash, has a significantly longer elimination half-life than ibuprofen. This difference in how the body processes the medicine aligns with the dosing schedule typically prescribed by healthcare providers.

Q: What ingredients are in Feldene Flash besides the main medicine?

A: The active ingredient is Piroxicam. Official drug labels for Piroxicam formulations may list excipients such as lactose monohydrate, starch, and other agents that help create the specific rapidly dissolving tablet. A complete list of inactive ingredients can be found in the official drug description.

Q: Can I take Feldene Flash if I have a sensitive stomach?

A: Official regulatory warnings emphasize that NSAIDs, including Piroxicam, carry an increased risk of serious gastrointestinal events such as bleeding and ulceration. For this reason, official guidance stresses using the lowest effective dosage for the shortest possible duration. Regulatory documents advise that the presence of such concerns warrants careful evaluation by a healthcare provider regarding potential risks.

Q: Can Feldene Flash interact with common over-the-counter allergy medicines?

A: Official drug interaction warnings advise against taking Feldene Flash with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which may be present in some common cold, flu, or allergy remedies. Combining these may increase the risk of side effects, particularly gastrointestinal issues, based on warnings for NSAID co-administration.

Q: Can older adults safely take Feldene Flash, or is it riskier?

A: Regulatory documents indicate that older adults are at a higher risk for experiencing the serious consequences of side effects, especially gastrointestinal bleeding and cardiovascular events. Official regulatory guidance emphasizes that in this population, treatment involves using the lowest effective dose for the shortest duration possible to mitigate risks.

Q: Does Feldene Flash affect fertility or reproductive health?

A: Official labeling notes that Piroxicam, like other NSAIDs, may temporarily and reversibly impair female fertility by delaying or preventing ovulation. Patients who are planning a pregnancy should seek appropriate medical guidance regarding this potential effect.

Q: What does recent medical research say about the long-term safety of Feldene Flash?

A: Regulatory warnings stress that the risk of serious side effects, including cardiovascular events (like heart attack and stroke) and gastrointestinal events (like bleeding and ulcers), may increase with the duration of use. Official guidance emphasizes that managing treatment requires using the lowest effective dose for the shortest duration to control symptoms.

Q: How quickly is Feldene Flash supposed to start working after I take it?

A: The lyophilisate formulation is designed for rapid delivery of the active ingredient, which helps achieve a faster onset of action. While the full therapeutic effect for chronic conditions may take time, the formulation promotes a faster onset of action, with effects sometimes reported shortly after administration.

Q: What are the most common reasons doctors prescribe Feldene Flash?

A: The officially approved indications for Feldene Flash are for the symptomatic treatment of specific chronic inflammatory and degenerative rheumatic diseases. These conditions include osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Q: Is it normal to feel a little dizzy after taking Feldene Flash?

A: Dizziness or vertigo is listed in the drug's official safety information as a documented adverse reaction. Patients experiencing dizziness or drowsiness should be aware that product information advises caution regarding activities like driving or operating machinery.

Q: Are there any foods or drinks that make Feldene Flash less effective?

A: Official product information explicitly states that co-administration with alcohol is associated with an increased risk of serious gastrointestinal complications. There are no general foods listed to make it less effective.

Q: How long does the pain relief from Feldene Flash usually last?

A: The active ingredient, Piroxicam, is known for its long elimination half-life. This sustained duration of action aligns with the typical regulatory guidance for this medicine, which is generally for once-daily administration.

Q: Does Feldene Flash affect sleep or cause insomnia?

A: Official safety documents list both insomnia (difficulty sleeping) and somnolence (drowsiness) as documented adverse reactions reported in association with this drug.

Q: Is there any research that shows how effective Feldene Flash is for arthritis?

A: Yes, Piroxicam is officially approved for the symptomatic relief of osteoarthritis and rheumatoid arthritis. This regulatory approval is based on research studies that established the efficacy of the active ingredient for these conditions.

Q: Why does the packaging say to be careful about sun exposure with Feldene Flash?

A: Official safety information lists photosensitivity as a documented adverse reaction. This means the medicine can increase the skin's sensitivity to sunlight, making it more prone to sunburn or rash.

Q: What happens if I miss a scheduled dose of Feldene Flash?

A: General patient instructions often advise that if a subsequent dose is due shortly, the missed dose should be skipped and the normal schedule resumed, rather than taking two doses close together. If a dose is missed, it should be taken as soon as the patient remembers, unless it is almost time for the next dose.

Q: How long does Feldene Flash stay in your system after you stop taking it?

A: Piroxicam has a very long elimination half-life, typically around 50 hours. Based on pharmacokinetics, it takes several days for the drug to be substantially cleared from the body after stopping treatment.

Q: Are there specific symptoms that mean I should stop taking Feldene Flash immediately?

A: Regulatory documents indicate the drug should be immediately discontinued if signs of serious side effects occur. These include signs such as chest pain, sudden weakness, or serious gastrointestinal symptoms like black or bloody stools, or vomiting that resembles blood.

Q: Can people with kidney problems use Feldene Flash?

A: Piroxicam is contraindicated in cases of severe kidney disease. For patients with less severe renal impairment, official guidance indicates the need for careful monitoring and potential adjustments to the prescribed regimen.

Q: What should I do if I feel heartburn after taking Feldene Flash?

A: Heartburn, or dyspepsia, is listed as a common side effect. Patient information often advises taking the drug with food if stomach upset occurs. If signs of serious events like severe pain or bleeding are suspected, patients should be aware that official warnings advise immediate discontinuation.

Q: Can Feldene Flash interact with herbal supplements like St. John's Wort?

A: Piroxicam is processed in the body by a specific enzyme called CYP2C9. Some herbal supplements, such as St. John's Wort, can affect this enzyme, potentially changing the levels of Piroxicam in the blood and impacting its effectiveness. Patients should ensure their healthcare provider is aware of all supplements being taken, as changes in drug levels may impact effectiveness.

Q: Is Feldene Flash suitable for post-operative pain management?

A: Regulatory warnings specifically state that Piroxicam is contraindicated (should not be used) for the treatment of pain right before or after coronary artery bypass graft (CABG) surgery.

Q: Does Feldene Flash have a maximum duration it can be safely used for?

A: Official guidance emphasizes using the lowest effective dosage for the shortest duration possible. For chronic conditions, regulatory information emphasizes that the benefit of continued treatment should be formally re-evaluated by the prescriber, often with an initial review within the first 14 days of starting therapy.

Q: Can I take Feldene Flash on an empty stomach?

A: Administration guidelines generally state that the drug is to be taken with or immediately after food. Taking the medicine with food helps to reduce the potential for gastrointestinal irritation.

Q: What types of pain is Feldene Flash not typically prescribed for?

A: The drug's officially approved indications are strictly limited to the symptomatic relief of chronic inflammatory and degenerative rheumatic diseases (OA, RA, AS). Uses for acute or non-inflammatory types of pain are not included in the official labeling.

Q: Are there any known side effects on mood or anxiety from Feldene Flash?

A: Official safety information lists reactions affecting the central nervous system. Documented but less common adverse reactions include reports of anxiety, confusion, depression, and other mood alterations.

Q: Is the 'fast' action of Feldene Flash due to how it's absorbed?

A: The rapid action is linked to the oral lyophilisate formulation. This design allows the tablet to disintegrate almost instantaneously, which facilitates the rapid delivery of Piroxicam for systemic absorption compared to conventional tablets.

Q: Can Feldene Flash cause skin rashes or increased sensitivity?

A: Yes, rash and photosensitivity skin reactions (increased sensitivity to the sun) are documented adverse reactions. In rare cases, the drug is also associated with serious, life-threatening skin conditions like Stevens-Johnson syndrome.

Q: Is it okay to drive or operate machinery after taking Feldene Flash?

A: Regulatory safety information indicates that because side effects like dizziness, vertigo, or drowsiness are possible, caution should be exercised regarding activities like driving or operating machinery.

Q: Does Feldene Flash interact with common cold or flu remedies?

A: Common cold and flu remedies that contain other NSAIDs or aspirin should be avoided. Official warnings advise against combining Piroxicam with other NSAIDs because of a significantly increased risk of serious gastrointestinal side effects.

Q: What is the shelf life of Feldene Flash, and how should it be stored?

A: The medicine must be kept in its original packaging and stored at a temperature not exceeding 30 C, protected from both moisture and light. The exact shelf life (expiration date) is marked on the product packaging and is also detailed in the official product information.

How should Feldene Flash be stored and disposed of?

The official storage and disposal guidelines for Feldene Flash (piroxicam oral lyophilisate) focus on maintaining its stability and ensuring safety.

Storage and Handling

  • Temperature: Store the medicine at room temperature, away from excessive heat. Storage must not exceed 30 C.
  • Protection: The product must be protected from moisture and light. It must be kept in the original container and sealed tightly closed to safeguard the rapid-dissolving tablets.
  • Child Safety: Always store Feldene Flash out of the sight and reach of children.

️ Disposal Requirements

  • Pharmaceutical Waste: Disposal of any unused or expired product must be done in accordance with local requirements for pharmaceutical waste.
  • Environmental Caution: Do not dispose of the medicine by flushing it down a toilet or throwing it into household wastewater, as Piroxicam is not on the FDA's 'Flush List'. Regulators recommend using a community drug take-back program when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Feldene Flash found in:

A-Z Index: